Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

People in Oxford who have osteoarthritis of the knee are being invited to take part in a national charity-funded clinical trial to find a more effective treatment.

Fiona Watt with PROMOTE trial
Fiona Watt with PROMOTE trial

The Arthritis Research UK clinical trial aims to find up to 160 people to take part around the country, at least eight patients will be recruited at the Nuffield Orthopaedic Centre, Oxford.

The trial will establish if a drug called methotrexate, commonly taken by people with rheumatoid arthritis, can also be effective in treating osteoarthritis: a completely different condition.

Osteoarthritis is a common condition of the joints, affecting around six million people in the UK, and caused largely by degeneration of cartilage at the ends of bones, and also inflammation, leading to pain and stiffness.

"Current treatments for knee osteoarthritis are limited in that they only work for short periods and are not suitable for many people," explained rheumatologist Dr Fiona Watt, who is leading the local arm of the trial.

"As a result, they often live with severe pain and have significant difficulty in carrying out their normal day-to-day activities. There is therefore an urgent need to find new and better ways of managing their pain."

Methotrexate is successfully and widely used to treat inflammation in rheumatoid arthritis, which is a serious auto-immune condition.

Recent studies have suggested that inflammation is also important in causing pain in osteoarthritis. Pilot studies which showed that 37% of patients with knee osteoarthritis who took methotrexate had a 40% reduction in their pain.

The clinical trial, run at the Nuffield Orthopaedic Centre by researchers from the Arthritis Research UK Centre for Osteoarthritis Pathogenesis, NDORMS, University of Oxford will recruit people with moderate to severe osteoarthritis of the knee, who are not getting benefit from traditional treatments such as painkillers. Half of those recruited will take methotrexate for 12 months and the other half will take a placebo tablet. Patients will also complete a questionnaire every three months.

To find out more please contact Angela Nauth, recruitment officer at the OA trials office at the University of Leeds, where the study is based, on 0113 3924965 or email oatrials@leeds.ac.uk

Similar stories

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

NDORMS researchers awarded Sir Henry Wellcome Fellowships

Kennedy Institute researchers Mariana Borsa and Edward Jenkins have both been awarded Sir Henry Wellcome Postdoctoral Fellowships, which give recently qualified postdoctoral researchers the opportunity to start independent research careers.